Mitoquinone-encapsulated iron-doped ceria nanoparticles functionalized with BSA for ROS-responsive and mitochondria-targeting therapy and care for acute kidney injury and fibrosis

Particulate Science And Technology, Год журнала: 2025, Номер unknown, С. 1 - 18

Опубликована: Апрель 2, 2025

Язык: Английский

Mitochondrial Dysfunction in Systemic Lupus Erythematosus: Insights and Therapeutic Potential

Diseases, Год журнала: 2024, Номер 12(9), С. 226 - 226

Опубликована: Сен. 23, 2024

Systemic lupus erythematosus (SLE) is a complex autoimmune disorder characterized by the presence of various serum autoantibodies and multi-system effects, predominantly affecting young female patients. The pathogenesis SLE involves combination genetic factors, environmental triggers, pathogen invasions that disrupt immune cell activation, leading to release chronic inflammation. Mitochondria, as primary cellular powerhouses, play crucial role in development through their control energy generation, reactive oxygen species (ROS) production, apoptotic pathways. Dysregulation mitochondrial structure function can contribute dysregulation, oxidative stress, inflammation seen SLE. Recent research has highlighted impact dysfunction on cells involved pathogenesis, such T-lymphocytes, B-lymphocytes, neutrophils, plasmacytoid dendritic cells. Mitochondrial these leads increased ROS disrupted mitophagy, alterations metabolism, contributing dysregulation Moreover, variations DNA (mtDNA) abnormalities dynamics have been linked SLE, exacerbating stress abnormalities. Targeting emerged promising therapeutic approach for Drugs sirolimus, N-acetylcysteine, coenzyme Q10, metformin shown potential restoring homeostasis, reducing modulating responses These agents demonstrated efficacy preclinical models clinical studies improving disease activity, autoantibody titers, ameliorating organ damage In conclusion, this review underscores critical mitochondria targeting novel strategy outcomes Further investigation into mechanisms underlying involvement targeted therapies hold promise advancing treatment enhancing patient care.

Язык: Английский

Mitochondria dysfunction: A trigger for cardiovascular diseases in systemic lupus erythematosus

International Immunopharmacology, Год журнала: 2024, Номер 144, С. 113722 - 113722

Опубликована: Дек. 1, 2024

Язык: Английский